How Molecular Glue Drugs Could Transform Autoimmune Disease Treatment Plans

Published :   18 Nov 2026  |  Author :  Aditi Shivarkar, Aman Singh  | 
 |  Copy Copy   Print Print

Molecular glue degraders offer a new approach to treating autoimmune diseases by targeting and removing harmful proteins. Explore emerging drug candidates, research breakthroughs, and their potential to improve treatment outcomes.

More than 90% of approved small molecules by regulatory authorities work by binding to an active site of the specific target protein and preventing it from carrying out its functions. However, about 80% of all proteins cannot be bound by traditional small-molecule drugs. This is because they either lack a well-defined binding site or the binding site is difficult to access. Targeted protein degradation (TPD) helps connect the target with a ubiquitin tag instead of binding to inhibit the target protein.

What are Molecular Glue Degraders?

Molecular glue degraders (MGDs) are a class of innovative small-molecule therapeutic agents within the field of TPD. MGDs induce protein degradation by stabilizing the interaction between an E3 ubiquitin ligase and a target protein. This leads to the formation of a ternary complex that facilitates ubiquitination and subsequent proteasomal degradation. MGDs offer several advantages over conventional small molecules, as they can bind to undruggable proteins, overcome resistance mechanisms, and achieve sustained pharmacological effects with lower drug concentrations.

Currently, three MGDs are approved for cancer treatment. These three include: thalidomide, lenalidomide, and pomalidomide. In recent years, with the continuous progress in TPD technologies, novel MGDs are being continually developed and translated into clinical applications. Some are in clinical trials, while others are still in the research stage.

MGDs were discovered accidentally in the 1990s. Thalidomide was initially prescribed as a sedative and antiemetic for morning sickness, but later withdrawn due to serious teratogenic effects. In 1994, the research team of oncologist Judah Folkman discovered that thalidomide inhibits angiogenesis. This was studied in a clinical trial involving 84 patients by Celgene, leading to an accelerated FDA approval in 2006.

The Table below lists Approved and Under-Development MGDs as of 2025 for Multiple Cancer Types and Autoimmune Ddiseases.

Compound Research Sponsor Development Phase Therapeutic Indication
Thalidomide Celgene Approved Multiple myeloma
Lenalidomide Celgene Approved Multiple myeloma
Pomalidomide Celgene Approved Multiple myeloma
CC-92480 Celgene Phase III Multiple myeloma, Relapsed/Refractory multiple myeloma
CC-220 Celgene Phase III Multiple myeloma
E7820 Eisai Phase II Myeloid neoplasms, Relapsed/refractory acute myeloid leukemia
CC-99282 Celgene Phase III Untreated high-risk large B-cell lymphoma
MRT-2359 Monte Rosa Phase I/II Lung cancer and other solid tumors
CFT-7455 C4 Therapeutics Phase I/II Relapsed/Refractory multiple myeloma
NVP-DKY709 Novartis Phase I Colorectal cancer, cutaneous melanoma
CC-90009 Celgene Phase I Acute myeloid leukemia; myelodysplastic syndromes
MRT-6160 Monte Rosa Phase I/II Autoimmune disease
SP-3164 Deuterx LLC Phase I Non-Hodgkin lymphoma; diffuse large B-cell lymphoma
PLX-4545 Lexium Phase I Multiple tumors

Emerging Opportunities in the Autoimmune Therapeutics Market

The rising prevalence of autoimmune disorders and the growing unmet clinical needs potentiate the need for novel therapeutics for autoimmune diseases. The most common autoimmune disorders that affect millions of people include rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and inflammatory bowel disease. It is estimated that the global prevalence of rheumatoid arthritis ranges from 0.1% to 2.0%.

Current treatment regimens for autoimmune disorders include conventional DMARDs, immunosuppressants, targeted immunotherapies, and CAR T-cell therapies. Despite the availability of these therapeutic agents, challenges in achieving sustained remission and reduced adverse effects persist. This increases the need to develop novel therapeutics for autoimmune disorders.

Protein degraders or MGDs are estimated to be revolutionary therapies for treating autoimmune disorders that act as precision medicines. They provide targeted actions by eliminating pathogenic proteins. This mechanism is essential when aberrant T-cell activation and differentiation drive the pathogenesis of autoimmune disorders. Ongoing research enables researchers to understand disease pathogenesis and potential targets to design precision medicine.

Spotlight in Innovation: Molecular Glue Candidates

Researchers from the University of Leeds discovered a new molecular glue that can dampen the activation of an enzyme called BRISC. BRISC plays a vital role in stabilizing the immune receptors in the active state by preventing their tagging for destruction with ubiquitin chains. The BRISC molecular glues (BLUEs) were able to lock two BRISC enzymes together. The BRISC complex can thereby stay available to transmit inflammatory signals driven by interferon, a key molecule involved in autoimmune diseases. Thus, BLUEs were found to reduce interferon signaling in cells, including in patients suffering from Scleroderma.

Scientists from the Baylor College of Medicine and NextGen Therapeutics developed BLUEs to neutralize harmful proteins related to blood cancers and autoimmune diseases. Compounds were derived using high-throughput proteomics. Their NGT-201-18 reduced VAV1 levels and suppressed T-cell activation, demonstrating that the degrader could alter immune-cell signaling in a biologically relevant setting. VAV1 degradation could become a useful strategy in treating autoimmune and inflammatory diseases.

Conclusion

Molecular glue degraders have proved to be a promising technique in the field of drug discovery and are expected to create novel opportunities to target those disease proteins that have remained challenging to target through conventional treatments. The use of these molecules would enable the overcoming of some of the challenges that conventional autoimmune treatments face, such as the inability to ensure remission and the occurrence of side effects. There is increasing research interest in this field and in the identification of molecular glues for autoimmune conditions, indicating transformation of the autoimmune therapeutics market.

The future of molecular glue degraders for autoimmune disorders is promising, driven by the development of new screening methods and the discovery of novel mechanisms of action. Researchers also make constant efforts to develop molecular glues that can selectively target specific protein isoforms or disease-relevant mutants. As research advances, molecular glue technology could open new avenues for more targeted and effective autoimmune therapies, potentially transforming the future of treatment for patients with chronic immune-mediated diseases.

About the Authors

Aditi Shivarkar

Aditi Shivarkar

Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.

Aman Singh

Aman Singh

Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.

Piyush Pawar

Piyush Pawar

Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.